Himalaya Early Access Program

Summary

To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with unresectable HCC.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications